NAS LABORATORY CO., LTD. is a contract research organization specializing in the housing, management, and evaluation of industrial and livestock animals. The company offers safety and functional assessments of the feed and veterinary pharmaceutical drugs at its in-house facilities. They provide non-clinical study that is tailored specifically to the livestock industry.
NAS LABORATORY CO., LTD. is a registered testing facility under Japan’s Ministry of Agriculture, Forestry and Fisheries (MAFF). They are authorized to conduct efficacy and safety evaluations for veterinary drugs and feed additives.
The laboratory has a particular strength in field trials, clinical studies, and pharmacological evaluations using livestock animals. By utilizing their own facilities, they offer an integrated system that covers a broad range of study types.
To ensure high data reliability, NAS LABORATORY CO., LTD. also participates in third-party proficiency testing programs. Backed by an advanced husbandry and management system, the laboratory delivers high-quality non-clinical research services specialized in livestock and veterinary science.
NAS LABORATORY CO., LTD. provides end-to-end support from protocol design and data collection to report preparation. They can also assist clients with documentation required for regulatory submissions.
Experienced staff with deep expertise in veterinary drug development provide consulting-level advice on regulatory pathways. Under a GLP-compliant quality management system, NAS LABORATORY CO., LTD. efficiently manages the entire workflow from study execution to documentation, offering flexible support in accordance to Japanese regulatory requirements.
The laboratory operates a wide range of facilities suitable for various livestock species, including beef cattle, dairy cattle, swine, and poultry. Study designs can be tailored to the biological characteristics and production environment of each species.
A key strength of NAS LABORATORY CO., LTD. is their capability to perform practical, field-oriented studies, such as evaluating feed additives under real farming conditions or conducting applied performance tests. Facility tours and pre-study consultations are also available. This enables future clients to collaboratively establish study frameworks that align with their project goals.
No case studies were available on the official website.
No case studies were available on the official website.
| Address | 1885-2 Komaino, Narita, Chiba, Japan |
|---|---|
| Tel | 0476-35-5766 |
| Website | https://www.naslabo.co.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.